Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, par value US$0.0001 per share
-
Shares outstanding
-
20,679,958
-
Total 13F shares
-
275,894
-
Share change
-
-68,714
-
Total reported value
-
$1,981,066
-
Put/Call ratio
-
57%
-
Price per share
-
$7.16
-
Number of holders
-
17
-
Value change
-
-$338,820
-
Number of buys
-
3
-
Number of sells
-
9
Institutional Holders of CASI Pharmaceuticals, Inc. - Ordinary Shares, par value US$0.0001 per share (CASI) as of Q4 2023
As of 31 Dec 2023,
CASI Pharmaceuticals, Inc. - Ordinary Shares, par value US$0.0001 per share (CASI) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
275,894 shares.
The largest 10 holders included
Wellington Shields Capital Management, LLC, Wellington Shields & Co., LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, FRANKLIN RESOURCES INC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, MORGAN STANLEY, UBS Group AG, and BlackRock Inc..
This page lists
17
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.